Q2 2024
Released Aug 13, 2024, after the close
10-Q filed Aug 13, 2024, 44 days after period end · 0001789769-24-000086
Q2 2024 · 10-Q
Revenue—
Net Income-$14.92M-$14.92M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$2.29-$2.29 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$14,135,000N/M
Operating Cash Flowderived-$10,612,000N/M
Free Cash Flowderived-$10,612,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$14.92M | -$18.66M | -$58.99M | -$35.31M |
| EPS Diluted | -$2.29 | -$2.87 | -$0.46 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR